Amanna Ian J, Slifka Mark K
Najít Technologies, Inc., Suite 200, Portland, OR 97201, USA.
Antiviral Res. 2009 Nov;84(2):119-30. doi: 10.1016/j.antiviral.2009.08.008. Epub 2009 Sep 4.
Vaccination is one of the most effective methods used for protecting the public against infectious disease. Vaccines can be segregated into two general categories: replicating vaccines (i.e., live, attenuated vaccines) and non-replicating vaccines (e.g., inactivated or subunit vaccines). It has been assumed that live attenuated vaccines are superior to non-replicating vaccines in terms of the quality of the antiviral immune response, the level of protective immunity, and the duration of protective immunity. Although this a prevalent viewpoint within the field, there are several exceptions to the rule. Here, we will explore the historical literature in which some of these conclusions have been based, including "Experiments of Nature" and describe examples of the efficacy of replicating vaccines compared to their non-replicating counterparts. By building a better understanding of how successful vaccines work, we hope to develop better "next-generation" vaccines as well as new vaccines against HIV--a pathogen of global importance for which no licensed vaccine currently exists.
接种疫苗是保护公众免受传染病侵害的最有效方法之一。疫苗可分为两大类:复制型疫苗(即减毒活疫苗)和非复制型疫苗(如灭活疫苗或亚单位疫苗)。人们认为,就抗病毒免疫反应的质量、保护性免疫的水平以及保护性免疫的持续时间而言,减毒活疫苗优于非复制型疫苗。尽管这是该领域的普遍观点,但也有一些例外情况。在这里,我们将探讨得出其中一些结论所依据的历史文献,包括“自然实验”,并描述复制型疫苗与其非复制型对应疫苗相比的有效性实例。通过更好地理解成功疫苗的作用机制,我们希望开发出更好的“下一代”疫苗以及针对艾滋病毒的新型疫苗——艾滋病毒是一种具有全球重要性的病原体,目前尚无获得许可的疫苗。